Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRI-Guided Hypofractionated Radiation Therapy for High Risk Prostate Cancer
NCT05676463Phase 2Terminated
- Sponsor
- Thomas Jefferson University
- Start
- Nov 2022
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in prostate cancer (PCa), sponsored by Thomas Jefferson University. Primary endpoint: Rate of late grade 2+ genitourinary (GU) toxicity at 1 year. Started Nov 2022; status: terminated.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05676463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05676463.